Biodesix's (BDSX) "Outperform" Rating Reaffirmed at William Blair

Biodesix (NASDAQ:BDSX - Get Free Report)'s stock had its "outperform" rating restated by stock analysts at William Blair in a research report issued on Tuesday,RTT News reports. William Blair also issued estimates for Biodesix's Q1 2025 earnings at ($0.08) EPS, Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at ($0.03) EPS, FY2025 earnings at ($0.22) EPS, Q1 2026 earnings at ($0.05) EPS, Q2 2026 earnings at ($0.03) EPS, Q3 2026 earnings at ($0.03) EPS, Q4 2026 earnings at ($0.03) EPS and FY2026 earnings at ($0.14) EPS.

Biodesix Price Performance

NASDAQ BDSX traded up $0.01 on Tuesday, reaching $0.86. The company's stock had a trading volume of 348,600 shares, compared to its average volume of 510,352. Biodesix has a twelve month low of $0.64 and a twelve month high of $2.04. The company has a debt-to-equity ratio of 1.30, a quick ratio of 3.40 and a current ratio of 3.40. The firm's 50 day moving average is $1.08 and its two-hundred day moving average is $1.40. The stock has a market cap of $125.42 million, a PE ratio of -2.21 and a beta of 1.10.

Biodesix (NASDAQ:BDSX - Get Free Report) last issued its earnings results on Monday, March 3rd. The company reported ($0.06) earnings per share for the quarter, topping analysts' consensus estimates of ($0.07) by $0.01. The firm had revenue of $20.43 million during the quarter, compared to analysts' expectations of $19.92 million. Biodesix had a negative net margin of 66.84% and a negative return on equity of 275.79%. As a group, sell-side analysts predict that Biodesix will post -0.35 EPS for the current year.

Remove Ads

Insider Activity

In other Biodesix news, CEO Scott Hutton sold 83,660 shares of Biodesix stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $0.92, for a total transaction of $76,967.20. Following the transaction, the chief executive officer now directly owns 701,947 shares in the company, valued at approximately $645,791.24. The trade was a 10.65 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders sold a total of 128,702 shares of company stock valued at $118,406 over the last three months. Insiders own 69.20% of the company's stock.

Institutional Trading of Biodesix

Hedge funds and other institutional investors have recently modified their holdings of the business. Wilmington Savings Fund Society FSB acquired a new position in Biodesix during the third quarter valued at $10,849,000. Samjo Management LLC purchased a new position in Biodesix during the 4th quarter valued at about $3,790,000. Susquehanna International Group LLP grew its stake in Biodesix by 769.8% during the 4th quarter. Susquehanna International Group LLP now owns 1,115,748 shares of the company's stock valued at $1,707,000 after acquiring an additional 987,475 shares in the last quarter. Silverarc Capital Management LLC increased its holdings in shares of Biodesix by 21.7% in the 4th quarter. Silverarc Capital Management LLC now owns 4,332,281 shares of the company's stock valued at $6,628,000 after purchasing an additional 771,187 shares during the period. Finally, AIGH Capital Management LLC lifted its position in shares of Biodesix by 8.8% in the fourth quarter. AIGH Capital Management LLC now owns 6,179,812 shares of the company's stock worth $9,455,000 after purchasing an additional 500,000 shares in the last quarter. Institutional investors and hedge funds own 20.96% of the company's stock.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.